Based on knowledge of the FGF7/FGFR2-IIIb interaction, bemarituzumab, which specifically targets FGF7’s receptor FGFR2b, would be of particular interest and may serve as a promising agent for future use in ovarian cancer. This evidence concerns the gene FGF7 and ovarian cancer.